Cochrane Database of Systematic Reviews · 2020 · 32 citations · 44 references
MedicineCardiologyPharmacologyClinical PharmacologyDrug DiscoveryMolecular PharmacologyCardiac MedicationsCardiovascular DiseaseCardiovascular PharmacologyGlucagon-like Peptide-1 Receptor AgonistsSodium-glucose Cotransporter 2 InhibitorsDipeptidyl PeptidasesGlucagon Receptor AgonistsGlucagon-like Peptide 1 Receptor AgonismGlucagon-like Peptide 1 SignalingGlucagon-like Peptide-1 Receptor SignalingGlucagon-like PeptidesSodium-glucose CotransportSodium-glucose Cotransporter 2 Inhibition
Objectives: \nThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: \n \nTo systematically review the available evidence on the effects (benefits and harms) of DPP‐4 inhibitors, GLP‐1 receptor agonists, and SGLT‐2 inhibitors in people with established CVD, using network meta‐analysis.
44
Bias in meta-analysis detected by a simple, graphical test
Matthias Egger, George Davey Smith, Martin Schneider et al. · BMJ · 1997 · 56.3K citations
John G.F. Cleland, Andrew J.S. Coats, Ewa A. Jankowska et al. · PubMed · 2021 · 19.5K citations
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text